Fate Therapeutics reported Q4 2025 revenue of USD 1.4 million and a net loss of USD 32.4 million, with total operating expenses of USD 36.1 million (including R&D expenses of USD 25.4 million and G&A expenses of USD 10.7 million). The company said it ended 2025 with USD 205.1 million in cash, cash equivalents and investments, and reported FY 2025 revenue of USD 6.6 million and a FY net loss of USD 136.3 million, alongside FY total operating expenses of USD 154.4 million (R&D USD 107.8 million; G&A USD 46.5 million). Shares outstanding as of Dec. 31, 2025 were 115.4 million common shares, with 3.9 million pre-funded warrants and 2.8 million preferred shares outstanding. On the business side, Fate Therapeutics highlighted outpatient dosing in its FT819-102 Phase 1 autoimmune basket trial, including same-day hospital discharge, and said the study is enrolling at 16 clinical sites across the U.S., U.K. and EU. As of Feb. 25, the company reported 15 systemic lupus erythematosus patients, four systemic sclerosis patients, and one idiopathic inflammatory myopathy patient treated with FT819; it also said the first systemic sclerosis patient reaching the 3-month evaluation timepoint showed improvements in HAQ, clinician global assessment, patient global assessment and modified Rodnan skin score under a less-intensive conditioning regimen. In oncology, Fate Therapeutics reported early activity for FT836 in colorectal cancer at dose level 1 without conditioning chemotherapy, including a greater than 50% reduction in CEA levels and approximately 20% tumor reduction in the sum of diameters at a 46-day scan in one patient treated in combination with cetuximab; three colorectal cancer patients have been treated at this dose level. The company projected an operating runway through year-end 2027 and cited a 30% reduction in operating expenses in 2025 compared to 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260900PRIMZONEFULLFEED9661903) on February 26, 2026, and is solely responsible for the information contained therein.
Comments